HRTDF

Heartseed Inc is a Japan-based company engaged in research and development of regenerative medicine products. The Company has established cardiac regenerative medicine, a therapy in which microtissue (cardiomyocytes) derived from iPS cells are transplanted into the heart, and conducts business activities for patients with severe heart failure. Target diseases include dilated cardiomyopathy (DCM), old myocardial infarction (OMI), and dilated-phase hypertrophic cardiomyopathy (D-HCM). Except the pipeline's leading cardiac treatment HS-001 (administration of regenerated myocardium derived from allogeneic iPS cells to the myocardium), the Company also conducts research into the creation of myocardium using autologous iPS cells that do not pose immune rejection reactions and iPS cells with HLA knockout.